GTBP GT Biopharma Inc

Price (delayed)

$7.1

Market cap

$12.81M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$100.75

Enterprise value

$7.76M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 8

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE ® NK cell engager platform. Our ...

Highlights
GTBP's EPS has soared by 73% since the previous quarter and by 72% year-on-year
The company's net income has surged by 54% QoQ and by 42% YoY
GT Biopharma's equity has surged by 114% YoY but it has shrunk by 53% QoQ
GT Biopharma's quick ratio has decreased by 39% QoQ

Key stats

What are the main financial stats of GTBP

GTBP stock price

How has the GT Biopharma stock price performed over time
Intraday
-1.11%
1 week
-9.09%
1 month
-1.66%
1 year
-65.57%
YTD
-63.83%
QTD
-41.99%

Financial performance

How have GT Biopharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$16.34M
Net income
-$22.08M
Gross margin
N/A
Net margin
N/A
The company's net income has surged by 54% QoQ and by 42% YoY
GTBP's operating income has dropped by 51% year-on-year and by 22% since the previous quarter

Price vs fundamentals

How does GTBP's price correlate with its fundamentals

Growth

What is GT Biopharma's growth rate over time

Valuation

What is GT Biopharma stock price valuation
P/E
N/A
P/B
2.87
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
GTBP's EPS has soared by 73% since the previous quarter and by 72% year-on-year
GT Biopharma's equity has surged by 114% YoY but it has shrunk by 53% QoQ
The price to book (P/B) is 32% higher than the last 4 quarters average of 2.2 and 7% higher than the 5-year quarterly average of 2.7

Efficiency

How efficient is GT Biopharma business performance
The company's return on assets rose by 41% QoQ and by 37% YoY

Dividends

What is GTBP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GTBP.

Financial health

How did GT Biopharma financials performed over time
GT Biopharma's total assets is 161% more than its total liabilities
The total liabilities has plunged by 93% YoY and by 8% from the previous quarter
GT Biopharma's total assets has decreased by 42% from the previous quarter and by 19% YoY
The debt is 100% lower than the equity
GT Biopharma's equity has surged by 114% YoY but it has shrunk by 53% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.